Research Article
The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
Table 2
Overall survival by baseline characteristics.
| | Characteristics | Alive (n = 327) | Died (n = 39) | value | | n | (%) | n | (%) |
| | Age (mean ± SD)# | 49.3 | ±9.3 | 51.5 | ±7.8 | 0.123 | | Tumor size (mm) (mean ± SD)# | 33.4 | ±18.4 | 50.5 | ±30.3 | <0.001 | | Neoadjuvant chemotherapeutic regimen | | | | | 0.090 | | Epirubicin-based | 169 | (51.7) | 14 | (35.9) | | | PLD-based | 158 | (48.3) | 25 | (64.1) | | | Molecular subtype | | | | | 0.024 | | Luminal type (Her2 negative) | 159 | (48.6) | 11 | (28.2) | | | Her2 positive | 114 | (34.9) | 16 | (41.0) | | | TNBC | 54 | (16.5) | 12 | (30.8) | | | Histological grade f | | | | | <0.001 | | Grade 1-2 (well/moderately differentiated) | 202 | (61.8) | 12 | (30.8) | | | Grade 3 (poorly differentiated) | 112 | (34.3) | 26 | (66.7) | | | Grade 9 (unknown) | 13 | (4.0) | 1 | (2.6) | | | Pathologic complete response (pCR) f | 68 | (20.8) | 1 | (2.6) | 0.011 | | Chemoregimen with taxane before surgery | 257 | (78.6) | 27 | (69.2) | 0.262 | | Clinical stage f | | | | | 0.016 | | IA | 24 | (7.3) | 0 | (0.0) | | | IIA | 116 | (35.5) | 10 | (25.6) | | | IIB | 138 | (42.2) | 18 | (46.2) | | | IIIA | 40 | (12.2) | 6 | (15.4) | | | IIIB | 8 | (2.4) | 4 | (10.3) | | | IIIC | 1 | (0.3) | 1 | (2.6) | | | Surgery | | | | | 0.046 | | Partial mastectomy | 143 | (43.7) | 10 | (25.6) | | | Total mastectomy | 184 | (56.3) | 29 | (74.4) | | | With radiotherapy | 240 | (73.4) | 31 | (79.5) | 0.531 |
|
|
Chi-square test. fFisher’s exact test. #Mann–Whitney U test. ; . |
